SCI Impact Surveys (2019)
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAMANAOAPAQARASATAUAVAWAXAYAZBABBBCBDBEBFBGBHBIBJBKBLBMBNBOBPBQ
1
For sources, see "Methods" sheet
2
Statistical significance of changes as reported by SCI is indicated by *s, where: ** = p < 0.01, * = p < 0.05. We have not verified these statistical tests.
3
Schistosoma haematobium
Schistosoma mansoni
HookwormAscarisTrichuris
4
Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)
5
CountryYearWhich follow-up?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Notes
6
Niger1st Follow-up75.4%38.0%-37.4%21.8%4.6%-17.2%
Very low prevalence
N/AN/AN/AN/AN/AN/AN/ALow prevalenceN/AN/AN/AN/AN/AN/AN/A
Very low prevalence
N/AN/AN/AN/AN/AN/AN/AFigures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
7
Burundi (pilot)
1st/3rd/4th Follow-up (see cell notes)
Very low prevalence
N/AN/AN/AN/AN/AN/AN/A12.7%1.7%-11.0%201-1917.8%2.7%-15.1%1624814.9%10.1%-4.8%3.2%2.4%-0.8%Figures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
8
Burundi (other schools)
1st/3rd/4th Follow-up (see cell notes)
Very low prevalence
N/AN/AN/AN/AN/AN/AN/A6.2%0.7%-5.5%83-515.1%5.4%-9.7%158-721.6%9.1%-12.5%10.4%4.3%-6.1%Figures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
9
Liberia20131st Follow-up20.2%9.0%-11.2%**9.0%2.5%-6.5%*26.2%15.0%-11.2%**0.2%1.0%0.8%*15.2%9.5%-5.7%Not reported
No participants heavily infected at baseline
N/AN/AN/A12.8%1.3%-11.5%Figures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
10
Cote d'Ivoire (Phase 1 schools)
20161st Follow-up7.5%9.2%1.7%No1.9%2.1%0.2%No5.984.66-1.32Not reported18.3%20.6%2.3%No2.9%1.9%-1.0%
Significant at 10% level
46.0127.86-18.15Not reported16.7%4.4%-12.3%**0.3%0.0%-0.3%N/A57.227.88-49.34Not reported3.2%1.2%-2.0%**0%0%0%N/A146.6726.02-120.65Not reported1.1%1.0%-0.1%No0%0%0%N/A21.416.69-14.72Not reported
11
Tanzania20171st Follow-up5.3%1.3%-4.0%**1.4%0.2%-1.2%**2.330.01-2.32**7.4%7.6%0.2%No1.1%1.0%-0.1%No2.3112.8910.58Not reported11.9%5.4%-6.5%Not reported0.0%0.0%0.0%N/A66.6714.97-51.70Not reported4.9%5.6%0.7%Not reported0%0%0%N/A141.5992.39-49.2Not reported1.7%4.1%2.4%Not reported0%0%0%N/A4.2110.506.29Not reportedSignificance tests taken from comments in commentary of dashboard, rather than results tables
12
Burundi20173rd Follow-upN/AN/AN/AN/AN/AN/AN/AN/A17.5%4.5%-13.0%**1.8%0.4%-1.4%**28.305.40-22.90**19.0%1.4%-17.6%**0%0%0.0%N/A19.601.80-17.80**8.2%3.0%-5.2%**0%0%0%N/A155.553.8-101.7**2.8%1.3%-1.5%**0%0%0%N/A1.70.8-0.9**
13
Madagascar20171st Follow-up30.8%25.2%-5.6%**15.3%8.0%-7.3%**62.3322.24-40.09**5.1%3.7%-1.4%*0.9%0.5%-0.4%*14.318.05-6.26N/A0.9%0.6%-0.3%No0%0%0.0%N/A2.293.701.41N/A3.0%7.2%4.2%**0%0%0%N/A116.42220.68104.26Not reported0.9%1.2%0.3%No0%0%0%N/A0.964.233.27Not reported
14
Ethiopia2016/171st Follow-up3.4%0.1%-3.3%Not reported0.2%0.0%-0.2%Not reported0.540.01-0.53Not reported5.6%5.5%-0.2%Not reported0.6%0.2%-0.4%Not reported10.405.54-4.86Not reported6.0%5.7%-0.3%Not reported0.01%0.01%0.0%Not reported11.1621.2810.12Not reported10.9%10.0%-0.9%Not reported0%0%0%N/A188.1205.417.3Not reported4.2%5.4%1.2%Not reported0%0%0%N/A8.2920.5712.28Not reported
15
Malawi20174th Follow-up9.2%2.4%-6.9%**1.6%0.5%-1.1%**3.590.57-3.02Not reported2.2%0.4%-1.8%*0.2%0.1%-0.1%No2.091.05-1.04Not reported0.0%0.1%0.1%N/A0%0%0.0%N/A0.00.020.0N/A0.0%0.0%0.0%N/A0%0%0%N/A000N/A0%0%0%N/A0%0%0%N/A000N/A
16
DRC 20172nd Follow-up0.8%0.0%-0.8%N/A0.8%0.0%-0.8%N/A8.300.00-8.30Not reported22.8%5.3%-17.5%**1.94%0.28%-1.66%**31.407.10-24.30Not reported0.0%0.3%0.3%No0.0%0.0%0.0%N/A0.00.00.0N/A2.5%3.3%0.8%No0%0%0%N/A78.602.00-76.60Not reported1.9%1.4%-0.6%No0%0%0%N/A1.300.30-1.00Not reported
17
Côte d'Ivoire2017
Note: Received but not reviewed
18
Liberia2018
Note: Received but not reviewed
19
Zanzibar2018
Note: Received but not reviewed
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...